Literature DB >> 35176168

Inhibiting WEE1 and IKK-RELA Crosstalk Overcomes TNFα Resistance in Head and Neck Cancers.

Carter Van Waes1, Ethan L Morgan1, Zhengbo Hu1,2, Ramya Viswanathan1, Hui Cheng1, Jianghong Chen1, Xinping Yang1, Angel Huynh1, Paul Clavijo3, Yi An1, Yvette Robbins3, Christopher Silvin1, Clint Allen3, Pinar Ormanoglu4, Scott Martin4, Shaleeka Cornelius1, Anthony Saleh1, Zhong Chen1.   

Abstract

TNFα is a key mediator of immune and radiotherapy-induced cytotoxicity, but many cancers, including head and neck squamous cell carcinomas (HNSCC), display TNF resistance due to activation of the canonical IKK-NF-κB/RELA pro-survival pathway. However, toxicities associated with direct targeting of the canonical pathway point to the need to identify mechanism(s) contributing to TNFα resistance and synthetic lethal targets to overcome such resistance in cancer cells. Here, RNAi screening for modulators of TNFα-NF-κB reporter activity and cell survival unexpectedly implicated the WEE1 and CDC2 G2-M checkpoint kinases. The IKKα/β-RELA and WEE1-CDC2 signaling pathways are activated by TNFα and form a complex in cell lines derived from both human papillomavirus (-) and (+) subtypes of HNSCC. WEE1 inhibitor AZD1775 reduced IKK/RELA phosphorylation and the expression of NF-κB-dependent pro-survival proteins Cyclin D1 and BCL2. Combination of TNFα and AZD1775 enhanced caspase-mediated apoptosis in vitro, and combination treatment with radiotherapy and AZD1775 potentiated inhibition of HNSCC tumor xenograft growth in vivo, which could be significantly attenuated by TNFα depletion. These data offer new insight into the interplay between NF-κB signaling and WEE1-mediated regulation of the G2-M cell-cycle checkpoint in HNSCC. IMPLICATIONS: Inhibiting WEE1 and IKK-RELA crosstalk could potentially enhance the effects of therapies mediated by TNFα with less systemic immune suppression and toxicity than observed with direct interruption of IKK-NF-κB/RELA signaling. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35176168      PMCID: PMC9177594          DOI: 10.1158/1541-7786.MCR-21-0624

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   6.333


  55 in total

1.  A probability-based approach for the analysis of large-scale RNAi screens.

Authors:  Renate König; Chih-yuan Chiang; Buu P Tu; S Frank Yan; Paul D DeJesus; Angelica Romero; Tobias Bergauer; Anthony Orth; Ute Krueger; Yingyao Zhou; Sumit K Chanda
Journal:  Nat Methods       Date:  2007-09-09       Impact factor: 28.547

Review 2.  Targeting IKK and NF-κB for Therapy.

Authors:  J K Durand; A S Baldwin
Journal:  Adv Protein Chem Struct Biol       Date:  2017-01-11       Impact factor: 3.507

Review 3.  Wee1 kinase as a target for cancer therapy.

Authors:  Khanh Do; James H Doroshow; Shivaani Kummar
Journal:  Cell Cycle       Date:  2013-08-26       Impact factor: 4.534

Review 4.  Regulation and function of IKK and IKK-related kinases.

Authors:  Hans Häcker; Michael Karin
Journal:  Sci STKE       Date:  2006-10-17

5.  Attenuated TRAF3 Fosters Activation of Alternative NF-κB and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers.

Authors:  Jialing Zhang; Tony Chen; Xinping Yang; Hui Cheng; Stephan S Späth; Paul E Clavijo; Jianhong Chen; Christopher Silvin; Natalia Issaeva; Xiulan Su; Wendell G Yarbrough; Christina M Annunziata; Zhong Chen; Carter Van Waes
Journal:  Cancer Res       Date:  2018-06-19       Impact factor: 12.701

6.  Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation.

Authors:  Noriaki Tanaka; Ameeta A Patel; Lin Tang; Natalie L Silver; Antje Lindemann; Hideaki Takahashi; Roman Jaksik; Xiayu Rao; Nene N Kalu; Tseng-Cheng Chen; Jiping Wang; Mitchell J Frederick; Faye Johnson; Frederico O Gleber-Netto; Siqing Fu; Marek Kimmel; Jing Wang; Walter N Hittelman; Curtis R Pickering; Jeffrey N Myers; Abdullah A Osman
Journal:  Clin Cancer Res       Date:  2017-08-08       Impact factor: 12.531

7.  Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.

Authors:  Abdullah A Osman; Marcus M Monroe; Marcus V Ortega Alves; Ameeta A Patel; Panagiotis Katsonis; Alison L Fitzgerald; David M Neskey; Mitchell J Frederick; Sang Hyeok Woo; Carlos Caulin; Teng-Kuei Hsu; Thomas O McDonald; Marek Kimmel; Raymond E Meyn; Olivier Lichtarge; Jeffrey N Myers
Journal:  Mol Cancer Ther       Date:  2014-12-10       Impact factor: 6.261

8.  CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia.

Authors:  Husheng Ding; Nicole D Vincelette; Cordelia D McGehee; Mira A Kohorst; Brian D Koh; Annapoorna Venkatachalam; X Wei Meng; Paula A Schneider; Karen S Flatten; Kevin L Peterson; Cristina Correia; Sun-Hee Lee; Mrinal Patnaik; Jonathan A Webster; Gabriel Ghiaur; B Douglas Smith; Judith E Karp; Keith W Pratz; Hu Li; Larry M Karnitz; Scott H Kaufmann
Journal:  Cancer Res       Date:  2021-01-07       Impact factor: 13.312

9.  Comprehensive genomic characterization of head and neck squamous cell carcinomas.

Authors: 
Journal:  Nature       Date:  2015-01-29       Impact factor: 49.962

10.  IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer.

Authors:  Carlota Colomer; Pol Margalef; Alberto Villanueva; Anna Vert; Irene Pecharroman; Laura Solé; Mónica González-Farré; Josune Alonso; Clara Montagut; Maria Martinez-Iniesta; Joan Bertran; Eva Borràs; Mar Iglesias; Eduard Sabidó; Anna Bigas; Simon J Boulton; Lluís Espinosa
Journal:  Mol Cell       Date:  2019-07-10       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.